Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses RNA Stabilization Technology to Celera

NEW YORK, Sept. 6-Ambion's diagnostics division has licensed its RNA stabilization technology to Celera Diagnostics, the company said today.


Through the deal, Celera gets nonexclusive worldwide rights to the technology, which it will use to develop molecular diagnostic assays. Ambion will also manufacture custom reagents for Celera.


Ambion's Armored RNA technology, a system jointly developed by Ambion and Centron, protects RNA by packaging it in bacteriophage coat proteins. The technique is useful in producing long-lasting, stable RNA controls for assays.


Celera Diagnostics is a joint venture between Celera Genomics and Applied Biosystems.


Ambion RNA Diagnostics is a division of Ambion, a RNA-focused tools company based in Austin, Texas.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.